The Department has been working with manufacturers of medicines used for the management of attention deficit hyperactivity disorder to ensure that action is taken to address the supply issues as quickly as possible. As a result of our continued work with the pharmaceutical industry, some issues have now been resolved, including with guanfacine. However, we know that there continue to be disruptions to the supply of some other medicines, including methylphenidate and lisdexamfetamine. We have been informed that these should be largely resolved by April or May 2024.

We understand how frustrating and distressing medicine shortages can be. While we cannot always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise and help mitigate risks to patients. We work with the pharmaceutical industry, NHS England, the devolved administrations, the Medicines and Healthcare products Regulatory Agency, and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when supply issues arise.

Disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD) have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. The Department has been working closely with the respective manufacturers and some issues have now been resolved. However, we know that there continue to be disruptions to the supply of some other medicines, which should resolve by April 2024.

We understand how frustrating and distressing medicine shortages can be and we want to assure patients that we are working with the respective manufacturers to resolve the issues with ADHD medicine supply in the United Kingdom as soon as possible and to help ensure patients are able to access these medicines, including methylphenidate, lisdexamfetamine, and guanfacine in the short and long term.

We have issued communications to the National Health Service to advise healthcare professionals on management of patients whilst there continue to be disruptions to supplies. Patients are advised to speak to their clinician regarding any concerns they have and to discuss the suitability of treatment with alternative medicines.

We are aware of disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD), including methylphenidate, lisdexamfetamine and guanfacine. Some issues have now been resolved. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. These issues are expected to resolve by the end of December 2023.

We understand how frustrating and distressing medicine shortages can be and we want to assure patients that we are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.

We have issued communications to the National Health Service to advise healthcare professionals on management of patients whilst there continue to be disruptions to supplies. Patients are advised to speak to their clinician regarding any concerns they have and to discuss the suitability of treatment with alternative medicines.

We are aware of supply issues affecting medicines used for the management of attention deficit hyperactivity disorder (ADHD). We have issued communications, in the form of a National Patient Safety Alert, to the National Health Service to advise healthcare professionals on the management of patients during this time. We continue to work closely with manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom. We have added ADHD products to the export restriction list to protect available supplies for UK patients. We anticipate that the supply disruption will resolve at various dates between October and December 2023. We do not hold information or take action at a local level.

We have published a list of currently available and unavailable ADHD products on the Specialist Pharmacy Services website, which provides information for prescribers. This will be regularly updated to ensure those involved in prescribing and dispensing can make informed decisions. Any patient who is impacted by this situation and has concerns about their treatment should discuss this with their clinician.

We are aware of supply issues affecting medicines used for the management of attention deficit hyperactivity disorder (ADHD). We have issued communications, in the form of a National Patient Safety Alert, to the National Health Service to advise healthcare professionals on the management of patients during this time. We continue to work closely with manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom. We have added ADHD products to the export restriction list to protect available supplies for UK patients. We anticipate that the supply disruption will resolve at various dates between October and December 2023. We do not hold information or take action at a local level.

We have published a list of currently available and unavailable ADHD products on the Specialist Pharmacy Services website, which provides information for prescribers. This will be regularly updated to ensure those involved in prescribing and dispensing can make informed decisions. Any patient who is impacted by this situation and has concerns about their treatment should discuss this with their clinician.